Mode
Text Size
Log in / Sign up

Immediate antihypertensive treatment for acute ischemic stroke may increase risks in specific blood pressure subgroupsTrial shows timing of blood pressure treatment affects stroke outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that immediate antihypertensive treatment may increase risk for patients with moderately elevated systolic blood pressure.

The study investigated the timing of antihypertensive treatment for patients presenting with acute ischemic stroke who had elevated systolic blood pressure and did not receive reperfusion therapy. The primary outcome was the incidence of functional dependency or death at a follow-up point. Researchers compared immediate treatment against delayed treatment starting later in the clinical course.

Findings indicated that early intervention was associated with an increased risk of poor outcomes specifically among patients with moderately elevated systolic blood pressure. In contrast, no significant differences were observed between early and delayed treatment strategies for patients with lower or higher systolic blood pressure ranges. Secondary outcomes, including stroke recurrence and major vascular events, showed no significant differences across any of the studied subgroups.

The authors noted that this analysis is a subgroup study of a larger trial, which may impact the certainty of the findings. Because these results are derived from specific subsets, they should be interpreted with caution when making clinical decisions. The data suggest that early antihypertensive treatment might carry different risks depending on the initial blood pressure level in patients with acute ischemic stroke.

When someone suffers an acute ischemic stroke, medical teams must make quick decisions about how to manage the patient's blood pressure. For many people, high blood pressure is a major concern during and after a stroke. This research looks specifically at whether treating that high blood pressure immediately—rather than waiting a few days—changes the chances of a patient remaining independent or surviving after 90 days.

The study involved a large group of over 4,800 patients who experienced an ischemic stroke. These patients had high systolic blood pressure (the top number in a reading) and did not receive immediate procedures to reopen blocked arteries. Researchers compared two different approaches: giving medication to lower blood pressure immediately versus waiting until the eighth day after the stroke to begin treatment.

The findings showed that the timing of treatment mattered, but specifically for patients with moderately high blood pressure. For those whose blood pressure was between 160 and 179 mmHg, starting treatment early was associated with a higher risk of functional dependency or death compared to waiting until day eight. However, for patients with lower blood pressure (under 160) or much higher blood pressure (over 180), the timing of the medication did not show a significant difference in outcomes.

It is important to understand that these results come from a subgroup analysis of a larger trial. This means the researchers looked at specific slices of the data rather than the primary goal of the original study. Because it is a subgroup analysis, the findings should be viewed with caution; they provide a helpful hint for doctors but are not definitive proof of how every patient will react to treatment.

For patients and families, this means that while managing blood pressure is critical after a stroke, the 'right' timing can depend on the specific numbers recorded during the emergency. Doctors use these types of studies to refine their guidelines. Currently, this research suggests that for some patients with moderate hypertension, a more cautious approach to lowering blood pressure immediately might be safer than aggressive early treatment.

What this means for you:
Early blood pressure treatment may increase risks for stroke patients with moderately high readings (160-179 mmHg).

Study Details

Study typeRct
Sample sizen = 4,802
EvidenceLevel 2
PublishedJul 2026
View Original Abstract ↓
OBJECTIVE: Whether initial systolic blood pressure (SBP) influences blood pressure management in acute ischemic stroke (AIS) and its association with outcome remains inconclusive. We conducted a subgroup analysis of CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to assess the impact of early vs. delayed antihypertensive treatment in AIS, stratified by baseline SBP. METHODS: CATIS-2 was a multicenter, randomized trial enrolling AIS patients within 24-48 h after onset, presenting with SBP 140-219 mmHg and without reperfusion therapy. Participants were randomized to receive immediate antihypertensive treatment or delayed treatment initiated on day 8. The primary outcome was functional dependency or death (modified Rankin Scale score ≥3) at 90-day. Three prespecified baseline SBP subgroups (<160, 160-179, and ≥180 mm Hg) were analyzed. RESULTS: 4802 patients (mean age 63.7 years, 65.0% male) were included, with baseline SBP < 160 mmHg ( n  = 2233), 160-179 mmHg ( n  = 1849), and ≥180 mmHg ( n  = 720). Among patients with baseline SBP 160-179 mmHg, early antihypertensive treatment was associated with increased risk of primary outcome compared to delayed treatment [13.3% vs. 10.4%; odds ratio (OR) 1.32, 95% confidence interval (CI) 1.00-1.76]. This finding was not observed in the baseline SBP < 160 mmHg subgroup (OR 1.12, 95% CI 0.84-1.50) or ≥180 mmHg subgroup (OR 0.98, 95% CI 0.66-1.46). No significant differences were found in stroke recurrence or major vascular events between treatment strategies across SBP subgroups. CONCLUSION: Early antihypertensive treatment may increase the risk of functional dependency or death in AIS patients with moderately elevated baseline SBP. These findings provide valuable insights into clinical practice regarding individualized blood pressure management in AIS. Further research is warranted. REGISTRATION: ClinicalTrials.gov (NCT03479554).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.